Sutro Biopharma Appoints New CMO, CFO, and Director
Ticker: STRO · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1382101
| Field | Detail |
|---|---|
| Company | Sutro Biopharma, Inc. (STRO) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, personnel
TL;DR
Sutro Biopharma shakes up exec team with new CMO, CFO, and board member.
AI Summary
Sutro Biopharma, Inc. announced on June 2, 2025, changes in its executive team and board. Dr. William D. Young has been appointed as the new Chief Medical Officer, and Ms. Jennifer L. Jones has joined as the new Chief Financial Officer. Additionally, Mr. David E. R. Gray has been elected to the Board of Directors.
Why It Matters
These executive and board changes could signal a new strategic direction or a focus on specific growth areas for Sutro Biopharma.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Sutro Biopharma, Inc. (company) — Registrant
- Dr. William D. Young (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Appointed Chief Financial Officer
- Mr. David E. R. Gray (person) — Elected to the Board of Directors
- June 2, 2025 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the newly appointed Chief Medical Officer, Dr. William D. Young?
The filing does not specify the exact responsibilities of Dr. William D. Young beyond his title as Chief Medical Officer.
What is the background of the new Chief Financial Officer, Ms. Jennifer L. Jones?
The filing does not provide details on Ms. Jennifer L. Jones's background or previous experience.
What is the tenure or term for Mr. David E. R. Gray on the Board of Directors?
The filing does not specify the term or tenure for Mr. David E. R. Gray's position on the Board of Directors.
Were there any departures of existing officers or directors mentioned in this filing?
The filing indicates "Departure of Directors or Certain Officers" as an item, but does not name any specific individuals who departed in the provided text.
What is the primary business of Sutro Biopharma, Inc. as stated in the filing?
Sutro Biopharma, Inc. is in the business of "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)" with SIC code 2836.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 by Dr. William D. Young regarding SUTRO BIOPHARMA, INC. (STRO).